Group 1 - Shandong Xishangxi New Materials Technology Co., Ltd. has terminated its IPO counseling status as of July 15, 2023, following a trend where three other Shandong companies also halted their IPO plans in July [1] - The company was established in June 2011 with a registered capital of 45.41 million yuan and has developed into a modern production enterprise for a full range of metal alcohol salts [2] - Xishangxi entered a counseling period with CITIC Securities on November 23, 2022, and underwent ten counseling sessions over 30 months, but ultimately decided to abandon its IPO plans [4] Group 2 - Zhiguan Technology Co., Ltd. also has a history of being listed on the New Third Board and initiated its A-share IPO counseling on October 8, 2023, despite facing significant financial losses in 2024 [5] - Zhiguan's revenue for 2024 was reported at 45.36 million yuan, a decline of 81.04% year-on-year, with a net loss of 49.04 million yuan, marking a 210.19% decrease [5] - Weisen New Materials Technology Co., Ltd. and Langhui Petrochemical Co., Ltd. also terminated their IPO counseling, with Weisen being a national high-tech enterprise focused on cellulose-based products [7][8] Group 3 - Langhui Petrochemical, established in December 2011 with a registered capital of 150 million yuan, specializes in fine chemical products and has faced challenges in its internal control systems [10] - The company reported revenues of 12.15 billion yuan, 12.69 billion yuan, and 13.41 billion yuan from 2022 to 2024, with net profits of 94.67 million yuan, 477 million yuan, and 213 million yuan respectively [10] - Langhui's debt levels are high, with a total liability of 3.368 billion yuan and a debt-to-asset ratio of 68.09% as of the end of 2024 [10]

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]

蓝帆医疗股份有限公司 上市公司名称：蓝帆医疗股份有限公司 股票上市地点：深圳证券交易所 股票简称：蓝帆医疗 股票代码：002382 信息披露义务人名称：山东朗晖石油化学股份有限公司 住所：淄博市临淄区金山镇经济开发区内 通讯地址：山东省淄博市临淄区一诺路 48 号 股份变动性质：同一控制人下的股份变动（增加） 签署日期：2025 年 5 月 16 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号—权益 变动报告书》、《公开发行证券的公司信息披露内容与格式准则第 16 号—上市公 司收购报告书》及其他相关的法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程及内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在蓝帆医疗股份有限公司中拥有权益的股份 变动情况。截至本报告书签署日，除本报告书披露的信息外，信息披露义务人没有 通过任何其他方式增加或减 ...